Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M29.2Revenue (TTM) $M0.1Net Margin (%)-32,717.1Altman Z-Score-20.3
Enterprise Value $M13.5EPS (TTM) $-2.3Operating Margin %-30,746.7Piotroski F-Score1
P/E(ttm)--Beneish M-Score-1.9Pre-tax Margin (%)-32,717.1Higher ROA y-yN
Price/Book3.510-y EBITDA Growth Rate %--Quick Ratio5.3Cash flow > EarningsY
Price/Sales3255-y EBITDA Growth Rate %--Current Ratio5.3Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-97.8Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-182.0Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M15.0ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with ARDM

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

ARDM is held by these investors:



ARDM: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Froehlich Juergen KurtChief Medical Officer 2016-10-04Sell423$6.76-71.15view
Froehlich Juergen KurtChief Medical Officer 2016-06-21Sell333$4.45-56.18view
THOMPSON VIRGILDirector 2013-12-13Sell84$6.8-71.32view
Grifols SADirector, 10% Owner 2013-08-27Sell0$0-71.32view
Boxer Capital, LLC10% Owner 2013-05-20Sell0$0-71.32view
DEF Associates Ltd.See footnote below 2012-01-01Sell0$0-71.32view
DEF Associates LPSee Footnote 1 below 2010-12-31Sell0$0-71.32view
First Eagle Value in BiotechnoSee remarks. 2009-02-23Sell0$0-71.32view
First Eagle Value in Biotechno10% Owner 2009-02-23Sell0$0-71.32view
Grimes D JefferyVP Legal Affairs, Secretary 2008-07-01Sell0$0-71.32view

Quarterly/Annual Reports about ARDM:

News about ARDM:

Articles On GuruFocus.com
First Eagle Adds to Stake in Aradigm Apr 28 2016 
Supernus Pharmaceuticals Reports Insider Buys Mar 26 2013 
Eveillard’s First Eagle Seizes 45% of Pharamaceutical Company, Aradigm Dec 19 2012 

More From Other Websites
Aradigm to Present at the Biotechnology Industry Organization (BIO) CEO & Investor Conference 2017... Feb 09 2017
Aradigm to Present at 9th Annual Biotech Showcase Conference on January 9 Jan 06 2017
ARADIGM CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits Dec 02 2016
Aradigm Lung Infection Antibiotic Fails Trial (ARDM) Dec 02 2016
Don’t Write Off Aradigm Corporation (ARDM) Just Yet Dec 02 2016
Aradigm Shares Plunge After Releasing Mixed Clinical Trial Results For Pulmaquin Dec 01 2016
Aradigm Announces Top-Line Results from Two Phase 3 Studies Evaluating Pulmaquin for the Chronic... Dec 01 2016
Aradigm Corp. drops 54% in pre-market trade on results of two late-stage clinical trials Dec 01 2016
Aradigm posts mixed late-stage data on inhaled antibiotic Dec 01 2016
Aradigm Announces Top-Line Results from Two Phase 3 Studies Evaluating Pulmaquin for the Chronic... Dec 01 2016
Aradigm Announces Top-Line Results from Two Phase 3 Studies Evaluating Pulmaquin for the Chronic... Dec 01 2016
ARADIGM CORP Financials Nov 18 2016
ARADIGM CORP Files SEC form 10-Q, Quarterly Report Nov 10 2016
Aradigm Corp. :ARDM-US: Earnings Analysis: Q3, 2016 By the Numbers : November 10, 2016 Nov 10 2016
Aradigm to Present at the Stifel 2016 Healthcare Conference on November 16 Nov 10 2016
ARADIGM CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Nov 09 2016
Aradigm Announces Third Quarter 2016 Financial Results Nov 09 2016
Aradigm Announces Third Quarter 2016 Financial Results Nov 09 2016
Multi-million Dollar DTRA Funding for Biodefense Research with Aradigm's Inhaled Ciprofloxacin Oct 18 2016
Multi-million Dollar DTRA Funding for Biodefense Research with Aradigm’s Inhaled Ciprofloxacin Oct 18 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)